Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer
Abstract:
Even with the decreasing incidence of colorectal cancer (CRC), data showing that the rate of incidence of CRC is declining with 2.9% every year starting with 2005 until 2014, CRC remains one of the most frequent neoplasia all over the world. Almost a quarter of patients with CRC present with stage IV disease at diagnosis and nearly 30% of patients with localized disease will progress within 5 years. Our study included 129 patients with metastatic CRC that received chemotherapy ± bevacizumab, from January 2017 until December 2018. Patients received fluropirimidine-based chemotherapy plus or minus bevacizumab. No significant differences was registered between groups with respects of age, sex, tumor localization, chemotherapy regimen used. Also no significant difference was found in our groups regarding risk factors for bleeding and medical history. No remarkable differences were registered between the two groups regarding common adverse reactions to chemotherapy, with the exception of physical asthenia which was found in a greater proportion of patients that received bevacizumab in combination with chemotherapy. In our study most frequent adverse events related to bevacizumab were grade 1 or 2, only few adverse events were grade 3 or 4 and lead to discontinuation of bevacizumab treatment, and these were mainly thromboembolic events and bleeding.
Cite this article as: GHEORGHE, A., ZOB, D., STANCULEANU, D., Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer, Rev. Chim., 71(1), 2020, 140-144.
Vancouver Gheorghe A, Zob D, Stanculeanu D. Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Rev. Chim.[internet]. 2020 Jan;71(1):140-144. Available from: https://doi.org/10.37358/RC.20.1.7824
APA 6th edition Gheorghe, A., Zob, D. & Stanculeanu, D. (2020). Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Revista de Chimie, 71(1), 140-144. https://doi.org/10.37358/RC.20.1.7824
Harvard Gheorghe, A., Zob, D., Stanculeanu, D. (2020). 'Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer', Revista de Chimie, 71(1), pp. 140-144. https://doi.org/10.37358/RC.20.1.7824
IEEE A. Gheorghe, D. Zob, D. Stanculeanu, "Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer". Revista de Chimie, vol. 71, no. 1, pp. 140-144, 2020. [online]. https://doi.org/10.37358/RC.20.1.7824
Text Andreea-Daniela Gheorghe, Daniela Zob, Dana-Lucia Stanculeanu, Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer, Revista de Chimie, Volume 71, Issue 1, 2020, Pages 140-144, ISSN 2668-8212, https://doi.org/10.37358/RC.20.1.7824. (https://revistadechimie.ro/Articles.asp?ID=7824) Keywords: metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events
RIS TY - JOUR T1 - Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer A1 - Gheorghe, Andreea-Daniela A2 - Zob, Daniela A3 - Stanculeanu, Dana-Lucia JF - Revista de Chimie JO - Rev. Chim. PB - Revista de Chimie SRL SN - 2668-8212 Y1 - 2020 VL - 71 IS - 1 SP - 140 EP - 144 UR - https://doi.org/10.37358/RC.20.1.7824 KW - metastatic colorectal cancer KW - bevacizumab KW - chemotherapy KW - adverse events ER -
BibTex @article{RevCh2020P140, author = {Gheorghe Andreea-Daniela and Zob Daniela and Stanculeanu Dana-Lucia}, title = {Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer}, journal = {Revista de Chimie}, volume = {71}, number = {1}, pages = {140-144}, year = {2020}, issn = {2668-8212}, doi = {https://doi.org/10.37358/RC.20.1.7824}, url = {https://revistadechimie.ro/Articles.asp?ID=7824} }